SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (14753)12/17/2004 5:02:25 PM
From: Biomaven  Read Replies (1) of 52153
 
I'd note also that in the CTIC Xyotax trials none of the surviving patients have been receiving any treatment for ages - the way the trials were designed they could receive a maximum of six courses of treatment (three weeks apart if I recall correctly - Erik can correct me if I'm confused at the end of a long week). I'm not quite sure why this was done - perhaps nobody expected anyone to receive even as much as six courses, given these are PS2 patients who traditionally don't tolerate much in the way of chemo at all.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News